Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors

Immunotherapy. 2020 Jul;12(10):675-679. doi: 10.2217/imt-2020-0142. Epub 2020 Jun 3.

Authors

Patrizia Vici¹, Laura Pizzuti¹, Eriseld Krasniqi¹, Andrea Botticelli², Gennaro Ciliberto³, Maddalena Barba¹

Affiliations

¹ Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
² Department of Clinical & Molecular Oncology, University of Rome "Sapienza", Rome, Italy.
³ Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

No abstract available

Keywords: Covid-19; immunotherapy; metastatic triple-negative breast cancer.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Betacoronavirus
COVID-19
Coronavirus Infections / diagnosis
Coronavirus Infections / epidemiology*
Female
Humans
Immunotherapy / adverse effects
Neoplasm Metastasis
Pandemics
Pneumonia, Viral / diagnosis
Pneumonia, Viral / epidemiology*
Practice Guidelines as Topic
Risk
SARS-CoV-2
Triple Negative Breast Neoplasms / epidemiology*
Triple Negative Breast Neoplasms / immunology
Triple Negative Breast Neoplasms / pathology
Triple Negative Breast Neoplasms / therapy*

Substances

Antineoplastic Agents, Immunological